drugset / Trial / NCT02881086

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

NCT02881086

Phase 3 Completed 1023 enrolled Goethe University
RandomizedParallel-groupOpen-labelTreatment

Summary

A phase IV study with the primary goal to optimize therapy of adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma (LBL) by dose and time intensive, pediatric based chemotherapy, risk adapted stem cell transplantation (SCT) and minimal residual disease (MRD) based individualised and intensified therapy. Study will further evaluate the role of asparaginase intensification, the extended use of rituximab and the use of nelarabine as consolidation therapy in T-ALL in a phase III-part of the study. Furthermore two randomisations will focus on the role of central nervous system (CNS) irradiation in combination with intrathecal therapy versus intrathecal therapy only in B-precursor ALL/LBL and the role of SCT in high-risk patients with molecular complete remission. Finally a new, dose reduced induction therapy in combination with Imatinib will be evaluated in Ph/BCR-ABL positive ALL.

Timeline

Start
2016-08
Primary completion
2024-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule
Subject Nelarabine Small molecule
Subject Pegaspargase Protein / enzyme biologic
Subject Rituximab Monoclonal antibody
Background Cyclophosphamide Other / unclassified
Background Cytarabine Small molecule
Background Daunorubicin Small molecule
Background Dexamethasone Small molecule
Background Doxorubicin Other / unclassified
Background Etoposide Small molecule
Background Fludarabine Small molecule
Background Idarubicin Small molecule
Background MERCAPTOPURINE ANHYDROUS Small molecule
Background Methotrexate Small molecule
Background Prednisolone Other / unclassified
Background Vincristine Small molecule
Background Vindesine Small molecule